Objective: To evaluate the effect of topical coenzyme Q10 (CoQ10) and vitamin E combination on tear function tests in glaucoma patients. Material and Methods: A combination drop of CoQ10 and vitamin E was inserted to one eye of 28 patients with glaucoma who have been using antiglaucomatous drops. The eyes that received the CoQ10 and vitamin E constituted the study group, and other eyes were part of the control group. Baseline, sixth, and twelfth-month tear function tests of the groups were evaluated. Results: Baseline values of Schirmer's test, tear meniscus, tear break-up time test, and corneal fluorescein staining did not significantly differ between the groups. When all values at baseline, six, and twelve months were compared, no difference was found in the study group, while a statistically significant decrease was observed in the mean of tear meniscus areas and tear meniscus depths in the control group (p=0.038, p=0.041, respectively). Conclusion: Although CoQ10 and vitamin E combination may positively eaffect tear function tests in patients with glaucoma, this effect was not statistically significant. Further studies with larger patient groups may help reveal the effects of these agents on glaucoma patients.
Keywords: Coenzyme Q10; dry eye; glaucoma; tear function test; vitamin E
Amaç: Glokom olgularında topikal koenzim Q10 [coenzyme Q10 (CoQ10)] ve E vitamini kombinasyonunun gözyaşı fonksiyon testleri üzerindeki etkisini değerlendirmek. Gereç ve Yöntemler: Antiglokomatöz damla kullanan 28 glokom olgusunun bir gözüne bir CoQ10 ve E vitamini kombinasyonu eklendi. CoQ10 ve E vitamini eklenen gözler çalışma grubunu diğer gözler kontrol grubunu oluşturdu. Grupların başlangıç, 6. ve 12. ayda yapılan gözyaşı fonksiyon testleri değerlendirildi. Bulgular: Schirmer testi, gözyaşı menisküs, gözyaşı kırılma zamanı testi ve kornea floresein boyamasının başlangıç değerleri gruplar arasında anlamlı farklılık göstermedi. Başlangıç, 6. ve 12. aydaki tüm değerler karşılaştırıldığında çalışma grubunda fark bulunmazken, kontrol grubunda gözyaşı menisküs alanları ve gözyaşı menisküs derinlikleri ortalamasında istatistiksel olarak anlamlı bir düşüş gözlendi (sırasıyla p=0,038, p=0,041). Sonuç: CoQ10 ve E vitamini kombinasyonu glokomlu olgularda gözyaşı fonksiyon testleri üzerinde olumlu bir etkiye sahip olmasına rağmen bu etki istatistiksel olarak anlamlı değildi. Daha büyük olgu gruplarıyla yapılacak ileri çalışmalar, bu ajanların glokom olguları üzerindeki etkilerini ortaya çıkarmaya yardımcı olabilir.
Anahtar Kelimeler: Koenzim Q10; kuru göz; glokom; gözyaşı fonksiyon testi; vitamin E
- Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262-7. [Crossref] [PubMed] [PMC]
- Labbé A, Terry O, Brasnu E, Van Went C, Baudouin C. Tear film osmolarity in patients treated for glaucoma or ocular hypertension. Cornea. 2012;31(9):994-9. [Crossref] [PubMed]
- Kaercher T, Hönig D, Barth W. How the most common preservative affects the Meibomian lipid layer. Orbit. 1999;18(2):89-97. [Crossref] [PubMed]
- Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312-34. [Crossref] [PubMed]
- Rossi GC, Tinelli C, Pasinetti GM, Milano G, Bianchi PE. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol. 2009;19(4):572-9. [Crossref] [PubMed]
- Saade CE, Lari HB, Berezina TL, Fechtner RD, Khouri AS. Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study. Can J Ophthalmol. 2015;50(2):132-6. [Crossref] [PubMed]
- Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29(6):618-21. [Crossref] [PubMed]
- Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II iatrojenic report. Ocul Surface 2017;15(3):276-83. [Crossref] [PubMed]
- Nebbioso M, Rusciano D, Pucci B, Zicari AM, Grenga R, Pescocolido N. Treatment of glaucomatous patients by means of food supplement to reduce the ocular discomfort: a double blind randomized trial. Eur Rev Med Pharmacol Sci. 2013;17(8):1117-22. [PubMed]
- Postorino EI, Rania L, Aragona E, Mannucci C, Alibrandi A, Calapai G, et al. Efficacy of eyedrops containing cross-linked hyaluronic acid and coenzyme Q10 in treating patients with mild to moderate dry eye. Eur J Ophthalmol. 2018;28(1):25-31. [Crossref] [PubMed]
- Fontaine E, Ichas F, Bernardi P. A ubiquinone-binding site regulates the mitochondrial permeability transition pore. J Biol Chem. 1998;273(40):25734-40. [Crossref] [PubMed]
- Nucci C, Tartaglione R, Cerulli A, Mancino R, Spanò A, Cavaliere F, et al. Retinal damage caused by high intraocular pressure-induced transient ischemia is prevented by coenzyme Q10 in rat. Int Rev Neurobiol. 2007;82:397-406. [Crossref] [PubMed]
- Lenaz G, Fato R, Castelluccio C, Genova ML, Bovina C, Estornell E, et al. The function of coenzyme Q in mitochondria. Clin Investig. 1993;71(8 Suppl):S66-70. [Crossref] [PubMed]
- Parisi V, Centofanti M, Gandolfi S, Marangoni D, Rossetti L, Tanga L, et al. Effects of coenzyme Q10 in conjunction with vitamin E on retinal-evoked and cortical-evoked responses in patients with open-angle glaucoma. J Glaucoma. 2014;23(6):391-404. [Crossref] [PubMed]
- Toshida H, Funaki T, Ono K, Tabuchi N, Watanabe S, Seki T, et al. Efficacy and safety of retinol palmitate ophthalmic solution in the treatment of dry eye: a Japanese Phase II clinical trial. Drug Des Devel Ther. 2017;11:1871-9. Erratum in: Drug Des Devel Ther. 2021;15:813-6. [Crossref] [PubMed] [PMC]
- Higuchi A. Development of new pharmaceutical candidates with antioxidant activity for the treatment of corneal disorders. Cornea. 2019;38 Suppl 1:S45-S9. [Crossref] [PubMed]
- Wei Y, Troger A, Spahiu V, Perekhvatova N, Skulachev M, Petrov A, et al. The role of SKQ1 (Visomitin) in inflammation and wound healing of the ocular surface. Ophthalmol Ther. 2019;8(1):63-73. [Crossref] [PubMed] [PMC]
- Abengózar-Vela A, Schaumburg CS, Stern ME, Calonge M, Enríquez-de-Salamanca A, González-García MJ. Topical quercetin and resveratrol protect the ocular surface in experimental dry eye disease. Ocul Immunol Inflamm. 2019;27(6):1023-32. [Crossref] [PubMed]
- Deinema LA, Vingrys AJ, Wong CY, Jackson DC, Chinnery HR, Downie LE. A randomized, double-masked, placebo-controlled clinical trial of two forms of omega-3 supplements for treating dry eye disease. Ophthalmology. 2017;124(1):43-52. [Crossref] [PubMed]
- Fogagnolo P, Sacchi M, Ceresara G, Paderni R, Lapadula P, Orzalesi N, et al. The effects of topical coenzyme Q10 and vitamin E D-α-tocopheryl polyethylene glycol 1000 succinate after cataract surgery: a clinical and in vivo confocal study. Ophthalmologica. 2013;229(1):26-31. [Crossref] [PubMed]
- Lulli M, Witort E, Papucci L, Torre E, Schipani C, Bergamini C, et al. Coenzyme Q10 instilled as eye drops on the cornea reaches the retina and protects retinal layers from apoptosis in a mouse model of kainate-induced retinal damage. Invest Ophthalmol Vis Sci. 2012;53(13):8295-302. [Crossref] [PubMed]
- Fato R, Bergamini C, Leoni S, Pinna A, Carta F, Cardascia N, et al. Coenzyme Q10 vitreous levels after administration of coenzyme Q10 eyedrops in patients undergoing vitrectomy. Acta Ophthalmol. 2010;88(4):e150-1. [Crossref] [PubMed]
- Bitton E, Wittich W. Influence of eye position on the Schirmer tear test. Cont Lens Anterior Eye. 2014;37(4):257-61. [Crossref] [PubMed]
- Gumus K. Topical coenzyme Q10 eye drops as an adjuvant treatment in challenging refractory corneal ulcers: a case series and literature review. Eye Contact Lens. 2017;43(2):73-80. [Crossref] [PubMed]
.: İşlem Listesi